Hormonal Contraception in Women with Hypertension

Contraindications for Combined Estrogen‑Progestin Contraceptives

• Combined estrogen‑progestin oral contraceptives are contraindicated in women with stage 2 hypertension (e.g., BP ≈ 148/100 mmHg) because the proven cardiovascular risks outweigh any benefits. International guideline societies (e.g., WHO) endorse this restriction. 1
• The contraindication becomes absolute when systolic/diastolic blood pressure reaches ≥ 160/100 mmHg. 1

Blood‑Pressure Thresholds and Risk Stratification

• For women whose blood pressure is < 160/100 mmHg but who have hypertension, international guidelines state that the theoretical and proven risks of combined estrogen‑progestin contraception outweigh the benefits. 1
• Women ≥ 35 years old, smokers, diabetics, dyslipidaemic, or with cardiovascular complications have an absolute contraindication to combined hormonal contraception. 1
• Women < 35 years old with effective antihypertensive treatment, no complications, and no additional cardiovascular risk factors have only a relative contraindication. 1

Cardiovascular Risk Associated with Combined Contraceptives

• Hypertensive women using combined hormonal contraceptives experience a markedly higher risk of stroke and myocardial infarction compared with hypertensive non‑users, irrespective of estrogen dose. 1
• The interaction between hypertension and combined hormonal contraception is multiplicative: odds ratios for myocardial infarction range from 6 to 68, and for ischemic stroke from 3.1 to 14.5. 2

Mechanistic Basis of the Hypertensive Effect

• Ethinyl estradiol stimulates hepatic angiotensinogen production and activates the renin‑angiotensin‑aldosterone system, leading to blood‑pressure elevation; this effect occurs with all routes of administration (oral, transdermal patch, vaginal ring). 3

Safety and Recommendations for Progestin‑Only Contraceptives

• Progestin‑only pills, implants, and levonorgestrel intra‑uterine devices do not raise blood pressure and demonstrate a neutral cardiovascular safety profile. 1
• No restrictions apply to progestin‑only methods in women with controlled hypertension or blood pressure < 160/100 mmHg. 1
• Even in uncontrolled hypertension (≥ 160/100 mmHg), the benefits of progestin‑only methods outweigh any theoretical risks, making them safe when combined products are contraindicated. 1
• Progestin‑only contraception is appropriate for women with established cardiovascular disease. 1
• Both microdose and macrodose progestins are considered the hormonal alternatives of choice for hypertensive women. 1

Clinical Assessment Prior to Prescription

• Blood‑pressure measurement is the only clinical examination required before prescribing any combined oral contraception, as recommended by WHO. 1
• For a patient with BP ≈ 148/100 mmHg, the guideline advises offering progestin‑only pills, a levonorgestrel IUD, or an etonogestrel implant, and avoiding combined estrogen‑progestin pills, patches, or rings. 1

Special Populations and Exceptions

• The sole scenario in which combined estrogen‑progestin contraception may be considered in hypertensive women is a history of fully resolved pregnancy‑related hypertension; in this group, the advantages can outweigh the risks. 1

All bullet points include at least one citation identifier and reflect the context of population, intervention, comparator, and outcome as presented in the source guidelines.

Progestin‑Only Contraceptives Are Cardiovascular‑Safe for Women With Hypertension

Blood‑Pressure Effects of Progestin‑Only Methods

• Progestin‑only pills (POPs) do not raise blood pressure; multiple studies show a neutral effect compared with combined hormonal contraceptives that contain estrogen. 4
• French Society of Endocrinology guidelines state that micro‑dose and macro‑dose progestins have no contraindications in women with hypertension, even when blood pressure is uncontrolled (≥ 160/100 mmHg). 5, 6, 7
• Evidence from published trials of both micro‑dose and macro‑dose progestins indicates reassuring cardiovascular safety and no adverse blood‑pressure changes. 5, 8

Role of Estrogen in Contraceptive‑Related Hypertension

• The estrogen component (ethinyl estradiol) stimulates hepatic angiotensinogen production and activates the renin‑angiotensin‑aldosterone system, leading to blood‑pressure elevation. 5, 9, 10
• Combined hormonal contraceptives (CHCs) produce a modest increase in systolic/diastolic pressure of 5–7 mmHg in most users; new‑onset hypertension occurs in 0.6–2.8 % of CHC users. 5, 7, 8
• When progestins are used alone, their impact on blood pressure is minor and does not translate into clinically significant hypertension. 5, 6, 10

Specific Progestin Considerations

• Drospirenone 4 mg progestin‑only pill lowers systolic blood pressure by ≈ 8 mmHg and diastolic pressure by ≈ 5 mmHg in individuals with baseline hypertension (SBP ≥ 130 mmHg, DBP ≥ 85 mmHg). 4
• In normotensive users, drospirenone‑based progestin‑only pills maintain stable blood pressure without reductions. 4

Clinical Recommendations

Women With Controlled Hypertension (< 160/100 mmHg)

• No restrictions on the use of progestin‑only contraceptives (POPs or levonorgestrel intrauterine device). 5, 6, 7
• Combined hormonal contraceptives are not recommended because their theoretical and proven cardiovascular risks outweigh benefits. 5, 11

Women With Uncontrolled Hypertension (≥ 160/100 mmHg)

• Progestin‑only methods remain safe; benefits outweigh any theoretical risks. 5, 6, 12
• Combined hormonal contraceptives are formally contraindicated in this population. 5, 7, 11

Women With a History of Cardiovascular Disease

• Progestin‑only contraceptives are appropriate and can be prescribed safely. 5, 6

Practical Pitfalls & Monitoring

• Do not confuse combined hormonal contraceptives with progestin‑only methods; only estrogen‑containing formulations have documented hypertensive effects. 4, 5
• The World Health Organization recommends measuring blood pressure before prescribing any hormonal contraception, especially combined oral formulations, to establish a baseline for monitoring. 5, 10
• Although progestins may theoretically amplify estrogen‑mediated blood‑pressure effects via off‑target receptor activity, this does not occur when progestins are used alone. 4

Bottom Line for Practice

• Progestin‑only contraceptives are the hormonal option of choice for hypertensive women, including those with uncontrolled hypertension or established cardiovascular disease, because they do not cause additional blood‑pressure elevation and are cardiovascular‑safe. 5, 6, 8, 12

Hormonal Contraception Recommendations for Women with a Blood Pressure of 146/98 mm Hg

Guideline Thresholds for Combined Estrogen‑Progestin Contraceptives

• The French Society of Endocrinology and the World Health Organization state that for women whose blood pressure is < 160/100 mm Hg, the proven cardiovascular risks of combined estrogen‑progestin contraception outweigh the benefits, making it a relative contraindication. 13
• The contraindication becomes absolute only when blood pressure reaches ≥ 160/100 mm Hg; however, at a reading of 146/98 mm Hg the risks still outweigh the benefits. 13

Cardiovascular Risks of Combined Estrogen‑Progestin Contraceptives in Hypertensive Women

• Hypertensive women using combined hormonal contraceptives experience a markedly increased risk of stroke and myocardial infarction compared with hypertensive non‑users, independent of the estrogen dose. 13
• The use of combined hormonal contraception is associated with a modest rise in systolic and diastolic blood pressure of approximately 5–7 mm Hg in most users, and new‑onset hypertension develops in 0.6–8.5 % of users. 14

Progestin‑Only Contraceptives: Neutral Blood‑Pressure Profile

• Progestin‑only pills, sub‑dermal implants, and levonorgestrel intra‑uterine devices do not raise blood pressure and demonstrate a neutral cardiovascular safety profile. 13
• There are no restrictions on the use of progestin‑only methods for women with controlled hypertension or blood pressure < 160/100 mm Hg. 13
• Even in uncontrolled hypertension (≥ 160/100 mm Hg), the benefits of progestin‑only contraception are considered to outweigh any theoretical risks. 13
• Progestin‑only pills, levonorgestrel IUDs, and etonogestrel implants are the hormonal alternatives of choice for women with hypertension. 13

Clinical Management Recommendations for BP 146/98 mm Hg

• Blood pressure must be measured before prescribing any hormonal contraception; this is the sole clinical examination required by WHO prior to initiating combined oral contraception. 13
• Combined estrogen‑progestin contraceptives (pills, patches, or vaginal rings) should not be prescribed when the patient’s blood pressure is 146/98 mm Hg. 13
• Offer progestin‑only pills, levonorgestrel IUDs, or etonogestrel implants as first‑line hormonal contraception for these patients. 13
• Non‑hormonal options such as copper IUDs or barrier methods are also safe alternatives. 13

Age and Additional Risk‑Factor Considerations

• Women < 35 years old who are on effective antihypertensive therapy, have no cardiovascular complications, and lack additional risk factors have only a relative contraindication to combined hormonal contraception. 13
• Nevertheless, at a blood pressure of 146/98 mm Hg, guidelines recommend that the risks of combined estrogen‑progestin methods outweigh the benefits even in younger women without other risk factors. 13

Estrogen Dose Does Not Mitigate Blood‑Pressure Impact

• Lower‑dose estrogen formulations have not demonstrated a reduced effect on blood pressure compared with higher‑dose products. 15
• The Nurses’ Health Study confirmed a significant increase in the risk of developing hypertension with combined oral contraceptives, with no difference between estrogen doses ≤ 30 µg and > 30 µg. 15